Obesity and Metabolic Syndrome: Debated Risk Factors for Prostate Diseases
Abstract
No abstract
References
1. Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, et al. The global obesity pandemic: Shaped by global drivers and local environments. Lancet. 2011; 378:804–814.
2. Ntuk UE, Gill JM, Mackay DF, Sattar N, Pell JP.Ethnic- Specific Obesity Cutoffs for Diabetes Risk: Cross-sectional Study of 490, 288 UK Biobank Participants. Diabetes Care. 2014 Jun 29. pii: DC_132966. [Epub ahead of print]
3. Bodicoat DH, Gray LJ, Henson J, Webb D, Guru A, Misra A, et al. Body mass index and waist circumference cut-points in multi-ethnic populations from the UK and India: the ADDITION-Leicester, Jaipur heart watch and New Delhi cross-sectional studies. PLoSOne 2014 Mar 5;9 :e90813.
4. Das M, Pal S, Ghosh A.Prevalence of the metabolic syndrome in people of Asian Iindian origin: outcomes by definitionsCardiovascular Journal of Africa 2011; 22: 303-305
5. Paresh D, Ahmad A, Ajay C, Priya M, Rajesh G. Metabolic Syndrome: A Comprehensive Perspective Based onInteractions Between Obesity, Diabetes, and Inflammation.
Circulation 2005, 111:1448-1454.
6. Yki-Jarvinen. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. The Lancet Diabetes & Endocrinology, Early Online Publication, 8 April 2014
7. Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J Urol. 2014 ; 30: 170–176
8. Giovannucci E, Rimm EB, Chute CG, Kawachi I, Colditz GA, Stampfer MJ, Willett WC. Obesity and Benign Prostatic Hyperplasia.Am. J. Epidemiol. (1994) 140 (11):989-1002.
9. Buschemeyer WC, Freedland SJ. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol. 2007; 52:331–43.
10. Antunes AA, Araújo LH, Nakano E, Muracca E, Srougi M. Obesity may influence the relationship between sex hormones and lower urinary tract symptoms. Int Braz J Urol. 2014; 40:240-6.
11. Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign prostatic hyperplasia: Clinical connections, emerging etiological paradigms and future directions. J Urol 2013; 189:S102-6.
12. Yuan-Yuan Qu,Bo Dai,Yun-Yi Kong,Kun Chang, Ding-Wei Ye, Influence of obesity on localized prostate cancer patients treated with radical prostatectomy Asian J Androl. Nov 2013; 15: 747–752.
13. Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani,S, Maggi M. Benign Prostatic Hyperplasia: A New Metabolic Disease ofthe Aging Male and Its Correlation with Sexual DysfunctionsInternational Journal of Endocrinology Volume 2014, Article ID 329456, 14 pages, http://dx.doi. org/10.1155/2014/329456
14. Elkahwaji JE. The role of inflammatory mediatorsin the development of prostatic hyperplasia and prostatic cancer. Research and Reports 2013;5: 1-10
15. Rundle A, Jankowski M,.Kryvenko ON. Obesity and Future Prostate Cancer Risk among Men after anInitial Benign Biopsy of the ProstateCancer Epidemiol Biomarkers Prev.2013; 22:898-904
16. Bhindi B, Kulkarni GS, Finelli A, Alibhai SM, Hamilton RJ, et al. Obesity Is Associated with Risk of Progression for Low-risk Prostate Cancers Managed Expectantly. Eur Urol. 2014 Jun 18. pii: S0302-2838(14)00526-0.doi: 10.1016/j.eururo. 2014.06.005. [Epub ahead of print]
17. Suburu J, Chen YQ. Lipids and prostate cancer. Prostaglandins Other Lipid Mediat. 2012;98:1-10.
18. Liang M, Mulholland DJ. Lipogenic metabolism: A viable target for prostatecancer treatment ? Asian J Androl. 2014 Jun 20.doi: 10.4103/1008-682X.132947. [Epub ahead of print]
19. Swierczynski J, Hebanowska A, Sledzinski T.Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. World J Gastroenterol.
2014; 20:2279-303
20. Swinnen JV, Heemers H, van de Sande T, de Schrijver E, Brusselmans K, Heyns W, Verhoeven G.Androgens, lipogenesis and prostate cancer. J Steroid BiochemMol Biol. 2004;92:273-9.
21. Melvin JC, Holmberg L, Rohrmann S, Loda Massimo,Van Hemelrijck M. Lipid Profiles and Cancer Risk in the Context of Obesity: Four Meta-Analyses J Cancer Epidemiol. 2013; 2013:823849.
22. Shiota M, Yokomizo A, Takeuchi A, Imada K, Kiyoshima K, et al. The feature of metabolic syndrome is a risk factor for biochemical recurrence after radical prostatectomy. J Surg Oncol. 2014 Jun 5.doi: 10.1002/jso.23677.
23. Asmar R, Beebe-Dimmer JL, Korgavkar K, Keele GR, Cooney KA. Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy.Prostate Cancer Prostatic Dis. 2013;16:62-6
24. Yamaoka K, Tango T. Effects of lifestyle modification on metabolic syndrome: a systematic review and meta-analysis. BMC Med. 2012 14;10:138
25. Discacciati A, Wolk A.Lifestyle and dietary factors in prostate cancer prevention. Recent Results Cancer Res. 2014; 202:27-37.
2. Ntuk UE, Gill JM, Mackay DF, Sattar N, Pell JP.Ethnic- Specific Obesity Cutoffs for Diabetes Risk: Cross-sectional Study of 490, 288 UK Biobank Participants. Diabetes Care. 2014 Jun 29. pii: DC_132966. [Epub ahead of print]
3. Bodicoat DH, Gray LJ, Henson J, Webb D, Guru A, Misra A, et al. Body mass index and waist circumference cut-points in multi-ethnic populations from the UK and India: the ADDITION-Leicester, Jaipur heart watch and New Delhi cross-sectional studies. PLoSOne 2014 Mar 5;9 :e90813.
4. Das M, Pal S, Ghosh A.Prevalence of the metabolic syndrome in people of Asian Iindian origin: outcomes by definitionsCardiovascular Journal of Africa 2011; 22: 303-305
5. Paresh D, Ahmad A, Ajay C, Priya M, Rajesh G. Metabolic Syndrome: A Comprehensive Perspective Based onInteractions Between Obesity, Diabetes, and Inflammation.
Circulation 2005, 111:1448-1454.
6. Yki-Jarvinen. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. The Lancet Diabetes & Endocrinology, Early Online Publication, 8 April 2014
7. Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J Urol. 2014 ; 30: 170–176
8. Giovannucci E, Rimm EB, Chute CG, Kawachi I, Colditz GA, Stampfer MJ, Willett WC. Obesity and Benign Prostatic Hyperplasia.Am. J. Epidemiol. (1994) 140 (11):989-1002.
9. Buschemeyer WC, Freedland SJ. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol. 2007; 52:331–43.
10. Antunes AA, Araújo LH, Nakano E, Muracca E, Srougi M. Obesity may influence the relationship between sex hormones and lower urinary tract symptoms. Int Braz J Urol. 2014; 40:240-6.
11. Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign prostatic hyperplasia: Clinical connections, emerging etiological paradigms and future directions. J Urol 2013; 189:S102-6.
12. Yuan-Yuan Qu,Bo Dai,Yun-Yi Kong,Kun Chang, Ding-Wei Ye, Influence of obesity on localized prostate cancer patients treated with radical prostatectomy Asian J Androl. Nov 2013; 15: 747–752.
13. Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani,S, Maggi M. Benign Prostatic Hyperplasia: A New Metabolic Disease ofthe Aging Male and Its Correlation with Sexual DysfunctionsInternational Journal of Endocrinology Volume 2014, Article ID 329456, 14 pages, http://dx.doi. org/10.1155/2014/329456
14. Elkahwaji JE. The role of inflammatory mediatorsin the development of prostatic hyperplasia and prostatic cancer. Research and Reports 2013;5: 1-10
15. Rundle A, Jankowski M,.Kryvenko ON. Obesity and Future Prostate Cancer Risk among Men after anInitial Benign Biopsy of the ProstateCancer Epidemiol Biomarkers Prev.2013; 22:898-904
16. Bhindi B, Kulkarni GS, Finelli A, Alibhai SM, Hamilton RJ, et al. Obesity Is Associated with Risk of Progression for Low-risk Prostate Cancers Managed Expectantly. Eur Urol. 2014 Jun 18. pii: S0302-2838(14)00526-0.doi: 10.1016/j.eururo. 2014.06.005. [Epub ahead of print]
17. Suburu J, Chen YQ. Lipids and prostate cancer. Prostaglandins Other Lipid Mediat. 2012;98:1-10.
18. Liang M, Mulholland DJ. Lipogenic metabolism: A viable target for prostatecancer treatment ? Asian J Androl. 2014 Jun 20.doi: 10.4103/1008-682X.132947. [Epub ahead of print]
19. Swierczynski J, Hebanowska A, Sledzinski T.Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. World J Gastroenterol.
2014; 20:2279-303
20. Swinnen JV, Heemers H, van de Sande T, de Schrijver E, Brusselmans K, Heyns W, Verhoeven G.Androgens, lipogenesis and prostate cancer. J Steroid BiochemMol Biol. 2004;92:273-9.
21. Melvin JC, Holmberg L, Rohrmann S, Loda Massimo,Van Hemelrijck M. Lipid Profiles and Cancer Risk in the Context of Obesity: Four Meta-Analyses J Cancer Epidemiol. 2013; 2013:823849.
22. Shiota M, Yokomizo A, Takeuchi A, Imada K, Kiyoshima K, et al. The feature of metabolic syndrome is a risk factor for biochemical recurrence after radical prostatectomy. J Surg Oncol. 2014 Jun 5.doi: 10.1002/jso.23677.
23. Asmar R, Beebe-Dimmer JL, Korgavkar K, Keele GR, Cooney KA. Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy.Prostate Cancer Prostatic Dis. 2013;16:62-6
24. Yamaoka K, Tango T. Effects of lifestyle modification on metabolic syndrome: a systematic review and meta-analysis. BMC Med. 2012 14;10:138
25. Discacciati A, Wolk A.Lifestyle and dietary factors in prostate cancer prevention. Recent Results Cancer Res. 2014; 202:27-37.
Published
2019-09-11
How to Cite
Rama Vaidya. (2019). Obesity and Metabolic Syndrome: Debated Risk Factors for Prostate Diseases. The Indian Practitioner, 67(7), 403-404. Retrieved from https://articles.theindianpractitioner.com/index.php/tip/article/view/776
Section
Editorial
